Published in Br J Clin Pharmacol on December 01, 1980
L-Tryptophan: Basic Metabolic Functions, Behavioral Research and Therapeutic Indications. Int J Tryptophan Res (2009) 1.29
Metabolism of an oral tryptophan load. II: Effect of pretreatment with the putative tryptophan pyrrolase inhibitors nicotinamide or allopurinol. Br J Clin Pharmacol (1980) 0.92
Metabolism of an oral tryptophan load III: effect of a pyridoxine supplement. Br J Clin Pharmacol (1980) 0.85
Use of tryptophan in combination with other antidepressant treatments: a review. J Psychiatry Neurosci (1991) 0.79
The pharmacokinetics of L-tryptophan following its intravenous and oral administration. Br J Clin Pharmacol (1985) 0.78
Metabolomics reveals the mechanisms for the cardiotoxicity of Pinelliae Rhizoma and the toxicity-reducing effect of processing. Sci Rep (2016) 0.76
Assessment of the Human Kynurenine Pathway: Comparisons and Clinical Implications of Ethnic and Gender Differences in Plasma Tryptophan, Kynurenine Metabolites, and Enzyme Expressions at Baseline and After Acute Tryptophan Loading and Depletion. Int J Tryptophan Res (2016) 0.76
SSRI Augmentation by 5-Hydroxytryptophan Slow Release: Mouse Pharmacodynamic Proof of Concept. Neuropsychopharmacology (2016) 0.75
Clinical and biochemical effects of parachlorophenylalanine in a patient with the carcinoid syndrome. Postgrad Med J (1982) 0.75
Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibitor and L-tryptophan. J Neurochem (1971) 3.34
The hormonal control of tryptophan peroxidase in the rat. J Biol Chem (1955) 3.19
The determination of tryptophan in plasma, liver, and urine. J Lab Clin Med (1967) 3.10
The effects of precursor loading in the cerebral metabolism of 5-hydroxyindoles. J Neurochem (1968) 2.30
The specific binding of L-tryptophan to serum albumin. J Biol Chem (1958) 2.20
Decrease of 5-hydroxytryptamine in the brain provoked by hydrocortisone and its prevention by allopurinol. Nature (1968) 1.69
Tryptamine metabolism in depression. Br J Psychiatry (1965) 1.54
The effect of tryptophan metabolites on brain 5-hydroxytryptamine metabolism. Biochem Pharmacol (1970) 1.41
Sequential comparison of L-tryptophan with E.C.T. in severe depression. Lancet (1970) 1.38
Assay of serotonin and related metabolites, enzymes, and drugs. Methods Biochem Anal (1958) 1.37
Letter: Factors influencing effect of hydrocortisone on rat brain tryptophan metabolism. Nature (1975) 1.27
Tryptophan loading: consequent effects on the synthesis of kynurenine and 5-hydroxyindoles in rat brain. J Neurochem (1978) 1.18
The determination of kynurenine in plasma. Clin Chim Acta (1975) 1.18
Transport of L-tryptophan into slices of rat cerebral cortex. J Neurochem (1972) 1.17
Relationships between plasma, CSF and brain tryptophan. J Neural Transm Suppl (1979) 1.05
Tryptophan in the treatment of depression. Lancet (1967) 1.00
L-tryptophan in affective disorders: indoleamine changes and differential clinical effects. Psychopharmacologia (1974) 0.98
Liver and brain tryptophan metabolism following hydrocortisone administration to rats and gerbils. Br J Pharmacol (1975) 0.97
Effects of albumin, amino acids, and clofibrate on the uptake of tryptophan by the rat brain. J Neurochem (1980) 0.95
Metabolism of an oral tryptophan load. II: Effect of pretreatment with the putative tryptophan pyrrolase inhibitors nicotinamide or allopurinol. Br J Clin Pharmacol (1980) 0.92
A study of proposed determinants of brain tryptophan concentration in rats after portocaval anastomosis or sham operation. J Neurochem (1978) 0.91
Tryptophan-nicotinamide, imipramine and their combination in depression. A controlled study. Acta Psychiatr Scand (1979) 0.91
Metabolism of an oral tryptophan load by women and evidence against the induction of tryptophan pyrrolase by oral contraceptives. Br J Clin Pharmacol (1978) 0.90
Unesterified fatty acids and the binding of tryptophan in human plasma. Clin Sci Mol Med (1974) 0.89
A simple apparatus for ultrafiltration of small volumes: application to the measurement of free and albumin-bound tryptophan in plasma. Anal Biochem (1977) 0.89
The effects of dietary tryptophan and its peripheral metabolism on brain-5-hydroxytryptamine synthesis and function. Essays Neurochem Neuropharmacol (1978) 0.89
Increased responsiveness to 5-methoxy-N,N-dimethyltryptamine in mice on a high tryptophan diet. Neuropharmacology (1979) 0.89
Demonstration, characterization, and assay procedure of tryptophan hydroxylase in rat brain. Anal Biochem (1966) 0.87
Tryptophan transport across the blood-brain barrier during acute hepatic failure. J Neurochem (1979) 0.81
Letter: Tryptophan/imipramine in depression. Lancet (1975) 0.81
L-tryptophan and 5-hydroxytryptophan in the treatment of depression. A review. Acta Psychiatr Scand (1978) 0.80
Effect of dietary protein on urinary 5-hydroxyindoleacetic acid levels. J Neurochem (1977) 0.78
Plasma tryptophan tolerance curves in drug free normal controls, schizophrenic patients and prisoner volunteers. J Psychiatr Res (1974) 0.78
Adverse drug reactions: definitions, diagnosis, and management. Lancet (2000) 16.12
Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med (2013) 8.89
Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med (2011) 7.89
Cross-cultural primary care: a patient-based approach. Ann Intern Med (1999) 5.06
Adverse drug reactions in a hospital general medical unit meriting notification to the Committee on Safety of Medicines. Br J Clin Pharmacol (1996) 4.50
Rapid method for the determination of 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in small regions of rat brain. Br J Pharmacol (1970) 4.48
High mortality among recipients of bought living-unrelated donor kidneys. Lancet (1990) 4.25
Analysis of vertebrate SCL loci identifies conserved enhancers. Nat Biotechnol (2000) 4.01
A gene-expression signature to predict survival in breast cancer across independent data sets. Oncogene (2006) 3.21
Ecstasy and neurodegeneration. BMJ (1996) 2.93
Total synthesis of a human leukocyte interferon gene. Nature (1981) 2.76
Oxidation phenotype--a major determinant of metoprolol metabolism and response. N Engl J Med (1982) 2.72
The cause of hepatic accumulation of fructose 1-phosphate on fructose loading. Biochem J (1970) 2.71
How to improve plastic surgery knowledge, skills and career interest in undergraduates in one day. J Plast Reconstr Aesthet Surg (2009) 2.54
Increased platelet aggregation responses to 5-hydroxytryptamine in patients taking chlorpromazine. Br J Clin Pharmacol (1975) 2.49
The SCL gene specifies haemangioblast development from early mesoderm. EMBO J (1998) 2.47
Multiple-dose activated charcoal for treatment of yellow oleander poisoning: a single-blind, randomised, placebo-controlled trial. Lancet (2003) 2.47
Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol (1981) 2.38
Incomplete evidence: the inadequacy of databases in tracing published adverse drug reactions in clinical trials. BMC Med Res Methodol (2001) 2.33
Medication errors, worse than a crime. Lancet (2000) 2.24
A prescription for better prescribing. Br J Clin Pharmacol (2006) 2.24
Dangers of intravenous fructose. Lancet (1972) 2.15
Inhibition of oxidative drug metabolism by beta-adrenoceptor antagonists in related to their lipid solubility. Br J Clin Pharmacol (1981) 2.08
Abnormal function of potassium channels in platelets of patients with Alzheimer's disease. Lancet (1998) 2.07
Molecular characteristics and prognostic features of breast cancer in Nigerian compared with UK women. Breast Cancer Res Treat (2012) 2.05
The mechanism of adenosine diphosphate induced platelet aggregation: binding to platelet receptors and inhibition of binding and aggregation by prostaglandin E 1 . J Physiol (1972) 2.05
Long-range comparison of human and mouse SCL loci: localized regions of sensitivity to restriction endonucleases correspond precisely with peaks of conserved noncoding sequences. Genome Res (2001) 2.04
Mechanism of the antidepressant action of electroconvulsive therapy. Lancet (1978) 2.03
BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. Br J Cancer (2010) 1.99
Tryptophan pyrrolase--a biochemical factor in depressive illness? Br J Psychiatry (1969) 1.98
Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol (2006) 1.97
Effects of immobilization and food deprivation on rat brain tryptophan metabolism. J Neurochem (1972) 1.96
Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. Br J Haematol (2005) 1.96
Free tryptophan in plasma and brain tryptophan metabolism. Nature (1972) 1.91
Rare diseases and orphan drugs. Br J Clin Pharmacol (2006) 1.83
Effects of drugs on the processes regulating the functional activity of brain 5-hydroxytryptamine. Nature (1976) 1.77
Balanced prescribing. Br J Clin Pharmacol (2006) 1.74
The prognostic significance of B lymphocytes in invasive carcinoma of the breast. Breast Cancer Res Treat (2011) 1.74
Accelerated ageing or selective neuronal loss as an important cause of dementia? Lancet (1979) 1.72
Analysis of pineal and brain indole alkylamines by gas chromatography-mass spectrometry. Adv Biochem Psychopharmacol (1973) 1.71
Decrease of 5-hydroxytryptamine in the brain provoked by hydrocortisone and its prevention by allopurinol. Nature (1968) 1.69
Effects on plasma and brain tryptophan in the rat of drugs and hormones that influence the concentration of unesterified fatty acid in the plasma. Br J Pharmacol (1974) 1.68
An SCL 3' enhancer targets developing endothelium together with embryonic and adult haematopoietic progenitors. Development (1999) 1.67
The SCL gene: from case report to critical hematopoietic regulator. Blood (1999) 1.65
Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies. Br J Clin Pharmacol (1985) 1.64
Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis. Gut (1982) 1.60
Effects of NXY-059 in experimental stroke: an individual animal meta-analysis. Br J Pharmacol (2009) 1.60
Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood (2000) 1.58
Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression. Histopathology (2007) 1.57
Measurement of specific [3H]-ouabain binding to different types of human leucocytes. Br J Clin Pharmacol (1984) 1.56
Cephalosporin-induced immune neutropenia. Br J Haematol (1985) 1.56
Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype. Br J Cancer (2008) 1.55
Lactate production in the perfused rat liver. Biochem J (1971) 1.54
Short-term primary culture of epithelial cells derived from human breast tumours. Br J Cancer (1998) 1.51
Lack of effect of atenolol on antipyrine clearance. Br J Clin Pharmacol (1982) 1.51
Electroconvulsive shock increases the behavioural responses of rats to brain 5-hydroxytryptamine accumulation and central nervous system stimulant drugs. Br J Pharmacol (1976) 1.48
The effects of putative 5-hydroxytryptamine antagonists on the behaviour produced by administration of tranylcypromine and L-tryptophan or tranylcypromine and L-DOPA to rats. Br J Pharmacol (1978) 1.48
Environmental impacts and sustainability of egg production systems. Poult Sci (2011) 1.46
The contribution of tryptamine to the behavioural effects of l-Tryptophan in tranylcypromine-treated rats. Psychopharmacology (Berl) (1978) 1.45
Monitoring digoxin therapy: I. Plasma concentrations and an in vitro assay of tissue response. Br J Clin Pharmacol (1977) 1.44
A behavioural and biochemical study in mice and rats of putative selective agonists and antagonists for 5-HT1 and 5-HT2 receptors. Br J Pharmacol (1985) 1.43
Rational prescribing, appropriate prescribing. Br J Clin Pharmacol (2004) 1.43
Prescribing statins. Br J Clin Pharmacol (2005) 1.42
Tumour-infiltrating macrophages and clinical outcome in breast cancer. J Clin Pathol (2011) 1.41
The effect of tryptophan metabolites on brain 5-hydroxytryptamine metabolism. Biochem Pharmacol (1970) 1.41
Distinct 5' SCL enhancers direct transcription to developing brain, spinal cord, and endothelium: neural expression is mediated by GATA factor binding sites. Dev Biol (1999) 1.41
The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man. Br J Clin Pharmacol (1982) 1.40
Iatrogenic chest pain: a case of 5-fluorouracil cardiotoxicity. QJM (1996) 1.39
Effects of monoamine oxidase inhibition by clorgyline, deprenil or tranylcypromine on 5-hydroxytryptamine concentrations in rat brain and hyperactivity following subsequent tryptophan administration. Br J Pharmacol (1975) 1.38
Proceedings: An isolated perfused rat brain--some histological and metabolic features. Clin Sci Mol Med (1974) 1.38
In defence of polypharmacy. Br J Clin Pharmacol (2004) 1.38
Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. J Pharmacol Exp Ther (1988) 1.37
Selective rescue of early haematopoietic progenitors in Scl(-/-) mice by expressing Scl under the control of a stem cell enhancer. Development (2001) 1.37
Lactic acidosis revisited. Diabetes (1983) 1.36
Quipazine: its effects on rat brain 5-hydroxytryptamine metabolism, monoamine oxidase activity and behaviour. Neuropharmacology (1976) 1.35
Evidence that hypophagia induced by mCPP and TFMPP requires 5-HT1C and 5-HT1B receptors; hypophagia induced by RU 24969 only requires 5-HT1B receptors. Psychopharmacology (Berl) (1988) 1.35
The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype. Br J Pharmacol (1995) 1.35
Further observations on the effect of repeated electroconvulsive shock on the behavioural responses of rats produced by increases in the functional activity of brain 5-hydroxytryptamine and dopamine. Psychopharmacology (Berl) (1977) 1.35
Cation transport functions in vitro in patients with untreated essential hypertension: a comparison of erythrocytes and leucocytes. Clin Sci (Lond) (1985) 1.34
Intermittent claudication: factors determining outcome. Br Med J (1978) 1.33
Emulating multicentre clinical stroke trials: a new paradigm for studying novel interventions in experimental models of stroke. Int J Stroke (2009) 1.32
Molecular cloning and chromosomal localization of the murine homolog of the human helix-loop-helix gene SCL. Proc Natl Acad Sci U S A (1991) 1.32
Metoprolol and debrisoquin metabolism in Nigerians: lack of evidence for polymorphic oxidation. Clin Pharmacol Ther (1986) 1.32
Inhibition of 5-hydroxytryptamine-induced human blood platelet aggregation by chlorpromazine and its metabolites. Br J Pharmacol (1975) 1.31
The effect of fatty acids on the binding of tryptophan to plasma protein. Nature (1973) 1.30
The pharmacology of the hypothermic response in mice to 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT). A model of presynaptic 5-HT1 function. Neuropharmacology (1985) 1.30
Digitalis intoxication. Clin Sci (Lond) (1983) 1.29
Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices. Br J Clin Pharmacol (1986) 1.29
Plagiarism - please don't copy. Br J Clin Pharmacol (2007) 1.29
Lignocaine and indocyanine green kinetics in patients following myocardial infarction. Br J Clin Pharmacol (1980) 1.28
Hypertension in multicultural and minority populations: linking communication to compliance. Curr Hypertens Rep (1999) 1.28
The Ets1 transcription factor is widely expressed during murine embryo development and is associated with mesodermal cells involved in morphogenetic processes such as organ formation. Proc Natl Acad Sci U S A (1993) 1.28
Letter: Factors influencing effect of hydrocortisone on rat brain tryptophan metabolism. Nature (1975) 1.27
Epidemiology of burns in childhood. Burns Incl Therm Inj (1984) 1.27